Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb

Cochrane Database of Systematic Reviews
Review (19 RCTs; n=1943) found more frequent complete clot lysis after thrombolysis (TS) with/without additional clot removal strategies and post‐thrombotic syndrome incidence was slightly reduced. Systemically administered and catheter‐directed TS have similar effectiveness.

Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation

British Journal of Clinical Pharmacology
Analysis of 4 cohorts (UK, Spain, Germany, Denmark,n = 251,719) found reduction in bleeding risk for DOACs doesn't resemble reductions found in trials. This could be at least partially attributable to nonadherence and limited external validity of trials, reflecting real‐life settings.

Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19

British Journal of Clinical Pharmacology
Understanding mechanisms underpinning hyperinflammation & coagulopathy is essential to formulating rationale therapeutic approaches beyond use of dexamethasone. Article reviews pathophysiology thought to underlie COVID‐19 with clinical correlates and therapies being investigated.

Patterns and factors influencing oral anticoagulant prescription in people with atrial fibrillation and dementia: Results from UK primary care

British Journal of Clinical Pharmacology
UK study found oral anticoagulant (OAC) prescriptions among patients with AF and dementia/cognitive impairment increased by 39.8% between 2000 and 2015. Characteristics related to frailty (e.g. history of falls, polypharmacy) were associated with lower odds of OAC prescription.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services